AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.
AbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
The U.S. Food and Drug Administration approved Catalyst Pharmaceuticals Inc.’s drug Firdapse to treat a rare autoimmune disease.
The Food and Drug Administration approved Bristol-Myers Squibb’s Opdivo for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.
AbbVie expect its flagship drug Humira to bring $21 billion in sales by 2020, about $3 billion higher than its expectation two years ago.